NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

Adding metformin to letrozole and abemaciclib (Verzenio) was tied to deep responses and prolonged progression-free survival ...

Head and neck squamous cell carcinomas responded better to a combination of two immunotherapies than to one immunotherapy ...

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

Discover GSK's impressive stock surge, boosted by strong earnings, a share buyback program, and a focus on specialty medicines.

Zymeworks shifts focus to ZW251 for liver cancer, delaying ZW220. Q4 revenue and earnings missed estimates. GSK milestone ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...